Several studies have examined what happens when patients switch from GLP-1 receptor agonists like semaglutide to tirzepatide, and the results are encouraging
Phentermine, an FDA-approved appetite suppressant since 1959, works through central nervous system stimulation, while tirzepatide (Zepbound, Mounjaro), approved in 2023 for obesity, operates through dual GIP/GLP-1 receptor pathways
This supports heart health by providing a complementary mechanism to offset the risks posed by high LDL levels
If your experience does not match your expectations, factors such as being early in your treatment plan, nutrition, health conditions, or other medications may play a role
Packer, M
Side effects drop significantly at lower doses, and costs can be one-quarter to one-third of standard therapy